natgillin/translations-raw huggingface dataset:
In multiple myeloma patients, the risk of renal dysfunction may be increased when intravenous bisphosphonates are used in combination with thalidomide.
U bolesnika s multiplim mijelomom, rizik od poremećaja funkcije bubrega može biti povećan kad se primjenjuju intravenski bisfosfonati u kombinaciji s talidomidom.
In multiple myeloma patients, the risk of renal dysfunction may be increased when Zoledronic acid Actavis is used in combination with thalidomide.
U bolesnika s multiplim mijelomom, rizik od poremećaja funkcije bubrega može biti povećan kad se Zoledronatna kiselina Actavis primjenjuje u kombinaciji s talidomidom.
In multiple myeloma, a cancer of a type of white blood cells called plasma cells, Revlimid is used:
U slučaju multiplog mijeloma, raka jedne vrste bijelih krvnih stanica, tzv. stanica plazme, Revlimid se primjenjuje:
In multiple myeloma, panobinostat is expected to keep genes that suppress the division and growth of the cancer cells switched ‘on’.
U slučaju multipla mijeloma, očekuje se da panobinostat zadrži uključenima gene koji sprječavaju dijeljenje i rast stanica raka.
In multiple sclerosis clinical studies first-degree atrioventricular block (prolonged PR interval on ECG) was detected after treatment initiation in 4.7% of patients on fingolimod 0.5 mg, in 2.8% of patients on intramuscular interferon beta-1a, and in 1.6% of patients on placebo.
U kliničkim ispitivanjima multiple skleroze, atrioventrikularni blok prvog stupnja (produljeni PR interval u elektrokardiogramu) bio je uočen nakon početka terapije u 4,7% bolesnika koji su primali fingolimod 0,5 mg, u 2,8% bolesnika koji su primali intramuskularni interferon beta-1a te u 1,6% bolesnika koji su primali placebo.
In multiple sclerosis clinical studies, the concomitant treatment of relapses with a short course of intravenous corticosteroids was not associated with a clinically relevant increase of infection.
U kliničkim ispitivanjima multiple skleroze, istodobno liječenje relapsa s kratkotrajnom intravenskom primjenom kortikosteroida nije bilo povezano s klinički relevantnim porastom infekcije.
In multiple sclerosis, the body’s immune (defence) system incorrectly attacks and damages the protective sheath around the nerve cells in the central nervous system (the brain and spinal cord).
Imunosni (obrambeni) sustav bolesnika s multiplom sklerozom greškom napada i oštećuje zaštitnu ovojnicu oko živčanih stanica u središnjem živčanom sustavu (mozgu i leđnoj moždini).
In multiple-dose studies, serum concentrations and AUC for norelgestromin and EE were found to increase only slightly over time when compared to week 1 cycle 1.
U ispitivanjima višestrukih doza, serumske koncentracije i AUC za norelgestromin i etinilestradiol povećavale su se neznatno kroz vrijeme u usporedbi s 1. tjednom 1. ciklusa.
in muscle, by increasing insulin sensitivity, improving peripheral glucose uptake and utilisation and delay of intestinal glucose absorption.
u mišiću, povećavajući osjetljivost na inzulin, poboljšavajući periferno preuzimanje i iskorištenost glukoze odgađajući intestinalnu apsorpciju glukoze.
in muscle, by increasing insulin sensitivity, improving peripheral glucose uptake and utilization, and delay of intestinal glucose absorption.
povećanjem osjetljivosti na inzulin u mišićima i time poboljšanjem perifernog unosa i iskorištavanja glukoze, i odgađanjem intestinalne apsorpcije glukoze.
in muscle, by increasing insulin sensitivity, improving peripheral glucose uptake and utilization, and delay of intestinal glucose absorption.
u mišiću, povećanjem osjetljivosti na inzulin, poboljšanjem perifernog unosa i iskorištavanja glukoze, i odgodom apsorpcije glukoze u crijevima.
in muscle, by modestly increasing insulin sensitivity, improving peripheral glucose uptake and utilisation by delaying intestinal glucose absorption
u mišićima, umjereno povećavajući osjetljivost na inzulin, čime se poboljšava pohrana i iskorištavanje glukoze u perifernim tkivima odgađajući apsorpciju glukoze u crijevima.
in muscle, by modestly increasing insulin sensitivity, improving peripheral glucose uptake and utilisation by delaying intestinal glucose absorption.
u mišićima, umjerenim povećavanjem osjetljivosti na inzulin, poboljšava periferni unos i iskorištenje glukoze usporavanjem intestinalne apsorpcije glukoze.
in muscle, by modestly increasing insulin sensitivity, improving peripheral glucose uptake and utilisation by delaying intestinal glucose absorption.
u mišićima, umjereno povećavajući osjetljivost na inzulin, čime se poboljšava pohrana i iskorištavanje glukoze u perifernim tkivima odgađajući apsorpciju glukoze u crijevima.
in muscle, by modestly increasing insulin sensitivity, improving peripheral glucose uptake and utilisation. by delaying intestinal glucose absorption.
u mišićima, skromnim povećanjem osjetljivosti na inzulin, poboljšavajući perifernu pohranu i iskorištavanje glukoze odgađanjem apsorpcije glukoze u crijevu.
in muscle, by modestly increasing insulin sensitivity, improving peripheral glucose uptake and utilisation; by delaying intestinal glucose absorption.
u mišićima umjerenim povećanjem osjetljivosti na inzulin, poboljšavajući periferni unos i korištenje glukoze; odgađanjem intestinalne apsorpcije glukoze.
In myelodysplastic syndromes patients, lenalidomide is associated with a higher incidence of grade 3 or 4 neutropenia (74.6% in lenalidomide-treated patients compared with 14.9% in patients on placebo in the Phase III study).
U bolesnika s mijelodisplastičnim sindromima, lenalidomid je povezan s višom incidencijom neutropenije ili 4. stupnja (74,6% u bolesnika liječenih lenalidomidom u usporedbi s 14,9% bolesnika koji su primali placebo u ispitivanju faze III).
In myelodysplastic syndromes, a group of bone marrow disorders that cause anaemia, Revlimid is used to manage patients in whom these lead to transfusion-dependent anaemia (low red blood cell counts severe enough to require blood transfusions).
U slučajevima mijelodisplastičnih sindroma, skupine poremećaja koštane srži koji uzrokuju anemiju, Revlimid se primjenjuje u liječenju bolesnika kod kojih ti poremećaji uzrokuju anemiju ovisnu o transfuziji (mali broj crvenih krvnih stanica koji je dovoljno ozbiljan da zahtijeva transfuziju krvi).
In myopic choroidal neovascularisation, Eylea was investigated in a main study involving 122 patients, which compared Eylea with a sham injection.
Kod miopne koroidne neovaskularizacije, lijek Eylea ispitivan je u glavnom ispitivanju koje je uključivalo 122 bolesnika, u kojem je lijek Eylea uspoređen s fiktivnom injekcijom.
In naltrexone / bupropion completed clinical studies, where naltrexone hydrochloride daily doses ranged from 16 mg to 48 mg, there were no cases of elevated transaminases >3x ULN in conjunction with an increase in bilirubin >2x ULN.
U završenim kliničkim ispitivanjima s naltrekson / bupropionom gdje su dnevne doze naltreksonklorida bile u rasponu od 16 mg do 48 mg, nije bilo slučajeva povišenih transaminaza >3x GGN povezanih s povećanjem bilirubina > 2x GGN.
In NEOSPHERE and TRYPHAENA trials in the neoadjuvant setting, hypersensitivity/anaphylaxis events were consistent with those observed in CLEOPATRA.
U ispitivanjima NEOSPHERE i TRYPHAENA, provedenima u neoadjuvantnim uvjetima, događaji preosjetljivosti/anafilaksije bili su u skladu s onima primijećenima u ispitivanju CLEOPATRA.
In newborn babies with special malformations of the heart, ‘what doctors calls congenital heart defects’ inhaled nitric oxide may cause a worsening of the circulation.
U novorođenčadi s posebnim srčanim malformacijama, koje liječnici nazivaju prirođenim srčanim manama, inhalacija dušikovog (II) oksida može uzrokovati pogoršanje cirkulacije.
In newly diagnosed chronic phase CML grade 4 neutropenia (ANC < 0.5 x 109/L) and thrombocytopenia (platelet count
U novodijagnosticiranoj kroničnoj fazi KML-a, neutropenija 4. stupnja (ABN
In newly diagnosed chronic phase CML grade 4 neutropenia (ANC < 0.5 x 109/l) and thrombocytopenia (platelet count < 10 x 109/l) were observed in 3.6% and < 1% of patients, respectively.
U novodijagnosticiranoj kroničnoj fazi KML-a, neutropenija stupnja (ABN <0,5 x 109/l) i trombocitopenija (broj trombocita <10 x 109/l) zapažene su u 3,6% odnosno <1% bolesnika.
In newly diagnosed multiple myeloma, Revlimid has been studied in two main studies, involving a total of around 2,000 patients, which looked at how long patients lived without their disease getting worse.
U novodijagnosticiranih multiplih mijeloma, Revlimid je ispitan u dva glavna ispitivanja, koja su obuhvatila ukupno otprilike 2.000 bolesnika, a istražila su koliko su dugo bolesnici živjeli bez pogoršanja bolesti.
In newly diagnosed patients there are two types of treatment:
U bolesnika s novodijagnosticiranim multiplim mijelomom postoje dvije vrste terapije:
In NexoBrid the powder containing concentrate of proteolytic enzymes enriched in bromelain is present in the form of a cake, reducing the likelihood of inhalational exposure.
U NexoBridu se prašak koji sadrži koncentrat proteolitičkih enzima obogaćenih bromelainom nalazi u obliku krutine, što smanjuje vjerojatnost izlaganja udisanjem.
In NexoBrid, the powder containing the concentrate of proteolytic enzymes enriched in bromelain is present in the form of a sterile lyophilised cake, reducing the likelihood of inhalational exposure.
U NexoBridu se prašak koji sadrži koncentrat proteolitičkih enzima obogaćenih bromelainom nalazi u obliku sterilne liofilizirane krutine, što smanjuje vjerojatnost izloženosti udisanjem.
In no case should there be more than 7 consecutive transdermal patch-free days.
Razdoblje bez primjene transdermalnog flastera, ne smije biti duže od 7 dana.
In non- responders, an increase in seizure frequency may be observed.
U pasa u kojih nema odgovora na liječenje, mogu se opaziti učestaliji napadaji.
In non- smoking individuals with mild (creatinine clearance 80-50 mL/min), moderate (creatinine clearance <50-30 mL/min) or severe (creatinine clearance <30 mL/min) renal impairment, riociguat plasma concentrations (AUC) were increased by 53%, 139% or 54%, respectively.
U nepušača s blagim (klirens kreatinina 80-50 ml/min), umjerenim (klirens kreatinina < 50-30 ml/min) ili teškim (klirens kreatinina < 30 ml/min) oštećenjem funkcije bubrega, koncentracije riocigvata u plazmi (AUC) bile su povećane za 53%, 139% odnosno 54%.
In non-clinical safety pharmacology, general toxicity, genotoxicity and carcinogenicity studies no clinically relevant effects have been observed, except those related to the pharmacological effect of the active substance.
U nekliničkim ispitivanjima sigurnosne farmakologije, opće toksičnosti, genotoksičnost i kancerogenosti nisu opaženi klinički važni učinci, osim oni povezani s farmakološkim učinkom djelatne tvari.
In non-clinical studies, Menveo had no direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development.
U nekliničkim ispitivanjima Menveo nije imao izravnih ili neizravnih štetnih učinaka na trudnoću, embrionalni/fetalni razvoj, porod ili postnatalni razvoj.
In non-diabetic patients with mild moderate and severe hepatic insufficiency (according to the Child- Pugh classification), mean AUC and Cmax of linagliptin were similar to healthy matched controls following administration of multiple 5 mg doses of linagliptin.
U bolesnika koji nemaju dijabetes, a imaju blagu, umjerenu i tešku insuficijenciju jetre (prema Child-Pughovoj klasifikaciji), prosječni AUC i Cmax linagliptina slični su odgovarajućim zdravim kontrolnim subjektima nakon primjene višestrukih doza 5 mg linagliptina.
In non-proliferating human peripheral blood mononuclear cells (PBMCs) the half-life of tenofovir diphosphate was found to be approximately 50 hours, whereas the half-life in phytohaemagglutinin- stimulated PBMCs was found to be approximately 10 hours.
U neproliferirajućih humanih mononuklearnih stanica periferne krvi (MSPK) utvrđeno je da je poluvijek tenofovirdifosfata oko 50 sati, a poluvijek u fitohemaglutinin stimuliranom MSPK-u oko 10 sati.
In non-smoking versus smoking subjects (males and females) the mean elimination half-life was prolonged (38.6 versus 30.4 hr) and the clearance was reduced (18.6 versus 27.7 l/hr).
Srednja vrijednost poluvremena eliminacije u ispitanika nepušača (muškarci i žene) bila je dulja nego u ispitanika pušača (38,6 naspram 30,4 sata), a klirens je bio manji (18,6 naspram 27,7 l/h).
In non-smoking versus smoking subjects (males and females) the mean elimination half-life was prolonged (38.6 versus 30.4 hr) and the clearance was reduced (18.6 versus 27.7 l/hr).
Srednje poluvrijeme eliminacije u ispitanika nepušača (muškarci i žene) bilo je duže nego u ispitanika pušača (38,6 u odnosu na 30,4 sata), a klirens je bio manji (18,6 u odnosu na 27,7 l/sat).
In non-squamous NSCLC, a higher number of deaths within 3 months was observed in nivolumab compared to docetaxel.
Kod neplanocelularnog NSCLC-a, u skupini liječenoj nivolumabom primijećen je veći broj smrtnih slučajeva unutar razdoblja od 3 mjeseca nego u skupini koja je primala docetaksel.
In nonclinical models, elotuzumab has demonstrated synergistic activity when combined with lenalidomide or bortezomib.
U nekliničkim je modelima elotuzumab ostvario sinergističko djelovanje u kombinaciji s lenalidomidom ili bortezomibom.
In none of these patients sunitinib was permanently discontinued.
Niti jednom bolesniku liječenje sunitinibom nije trajno obustavljeno.
In normal cells there is an alternative mechanism for repairing DNA which requires BRCA1 and BRCA2 proteins.
U normalnih stanica postoji alternativan mehanizam za popravak DNK koji zahtjeva BRCA1 i BRCA2 proteine.
In normal cells, homologous recombination repair (HRR), which requires functional BRCA1 and 2 genes, is effective at repairing these DNA double-strand breaks.
U normalnim se stanicama ti dvolančani lomovi DNK učinkovito popravljaju homolognom rekombinacijom, za koju su neophodni funkcionalni geni BRCA1 i 2.
In normal condition of use, transient apathy and anorexia may occasionally occur, as well as hyperthermia (lasting usually for 1 or 2 days).
U normalnim uvjetima primjene povremeno se mogu javiti apatija i anoreksija, kao i hipertermija (obično u trajanju od 1 ili 2 dana).
In normal conditions of use, transient apathy and anorexia may occasionally occur, as well as hyperthermia (lasting usually for 1 or 2 days).
U normalnim uvjetima primjene, povremeno se mogu javiti apatija i anoreksija, kao i hipertermija (u trajanju 1 ili 2 dana).
In normal conditions of use, transient apathy and anorexia may occasionally occur, as well as hyperthermia (lasting usually for 1or 2 days).
U normalnim uvjetima primjene, povremeno se mogu javiti apatija i anoreksija, kao i hipertermija (u trajanju obično 1 ili 2 dana).
In normal donors, a 10 micrograms/kg/day dose administered subcutaneously for 4 - 5 consecutive days allows a collection of ≥ 4 x 106 CD34+ cells/kg recipient body weight in the majority of the donors after two leukaphereses.
U zdravih darivatelja, doza od 1 MU/kg/dan (10 mikrograma/kg/dan) koja se primjenjuje potkožno tijekom 4-5 dana uzastopno omogućuje prikupljanje ≥ 4 x 106 CD34+ stanica/kg tjelesne težine primatelja u većine darivatelja nakon dvije leukafereze.
In normal donors, dyspnoea has been reported commonly and other pulmonary adverse events (haemoptysis, pulmonary haemorrhage, lung infiltrates and hypoxia) have been reported uncommonly.
U zdravih je davatelja često zabilježena dispneja, a manje često drugi plućni štetni događaji (hemoptiza, plućna hemoragija, plućni infiltrati i hipoksija).
in normal stem cell donors
kod zdravih davatelja matičnih stanica
in normal stem cell donors
u zdravih darivatelja matičnih stanica
In normal stem cell donors
U zdravih davatelja progenitorskih stanica
In nr-Axial SpA, antibodies to golimumab were detected in 4% (4/93) of golimumab treated patients through week 16 by the EIA method.
U aksijalnom spondiloartritisu bez radiološkog dokaza, protutijela na golimumab otkrivena su EIA metodom u 7% (14/193) bolesnika liječenih golimumabom do 52. tjedna.
In NSCLC that had spread locally or to other parts of the body, Opdivo has been shown to improve the average time patients survived compared with docetaxel (another cancer medicine).
Kod raka pluća nemalih stanica (NSCLC) koji se proširio lokalno ili na druge dijelove tijela, pokazalo se da Opdivo poboljšava prosječno vrijeme preživljavanja bolesnika u usporedbi s docetakselom (drugim lijekom protiv raka).
In obese hypertensive patients who did not adequately respond to HCTZ 25 mg, add-on treatment with Rasilez 300 mg provided additional blood pressure reduction that was comparable to add-on treatment with irbesartan 300 mg or amlodipine 10 mg.
U pretilih hipertenzivnih bolesnika koji nisu odgovarajuće odgovorili na HCTZ u dozi od 25 mg, dodatno liječenje Rasilezom u dozi od 300 mg dovelo je do dodatnog sniženja krvnoga tlaka koje se moglo usporediti s dodatnim liječenjem od 300 mg irbesartana ili 10 mg amlodipina.
In obese type 2 diabetic patients insufficiently controlled by antidiabetic agents, data from four one- year clinical trials showed that the percentage of responders ( 10 % of body weight loss) was 11.3 % with orlistat as compared to 4.5 % with placebo.
U pretilih bolesnika s dijabetesom tipa II koji nisu u potpunosti kontrolirani antidijabeticima, podaci iz četiri jednogodišnje studije pokazuju da je postotak onih koji su odgovorili na terapiju ( 10 % gubitka tjelesne težine) bio 11,3 % uz primjenu orlistata u usporedbi s 4,5 % uz primjenu placeba.
In older or overweight patients, lower doses may be necessary.
Kod pretilih bolesnika, mogu biti potrebne niže doze.
In older patients (≥ 65 years old) and in patients with hepatic or renal impairment, glucose monitoring should be intensified and the insulin aspart dose adjusted on an individual basis.
U starijih bolesnika (≥ 65 godina) i u bolesnika s oštećenjem jetre ili bubrega treba pojačano pratiti razine glukoze te individualno prilagoditi dozu aspart inzulina.
In older patients, glucose monitoring should be intensified and the insulin aspart dose adjusted on an individual basis.
U starijih bolesnika treba pojačano pratiti razine glukoze te individualno prilagoditi dozu aspart inzulina.
In older patients, glucose monitoring should be intensified and the Levemir dose adjusted on an individual basis.
U starijih bolesnika treba pojačano pratiti razine glukoze te individualno prilagoditi dozu lijeka Levemir.
In older pigs, or in pigs with reduced appetite, or on restricted feed intake, inclusion levels may need to be increased to achieve target dose.
U starijih svinja ili svinja s oslabljenim apetitom, ili kad je unos hrane ograničen, razine dodavanja možda treba povećati kako bi se dosegla ciljna doza.
In older pigs, or in pigs with reduced appetite, or on restricted feed intake, inclusion levels may need to be increased to achieve target dose.
U starijih svinja ili svinja s oslabljenim apetitom, ili kad je unos hrane za životinje ograničen, razine dodavanja možda treba povećati kako bi se dosegla ciljna doza.
In one 3-year, randomised, double-blind controlled trial that evaluated the efficacy and safety of zoledronic acid 5 mg once yearly vs. placebo in the treatment of postmenopausal osteoporosis (PMO), the overall incidence of atrial fibrillation was 2.5 % (96 out of 3,862) and 1.9 % (75 out of 3,852) in patients receiving zoledronic acid 5 mg and placebo, respectively.
U jednom randomiziranom, dvostruko slijepom, kontroliranom ispitivanju u trajanju od 3 godine u kojem se ocjenjivala djelotvornost i sigurnost zoledronatne kiseline u dozi od 5 mg jedanput godišnje u usporedbi s placebom u liječenju postmenopauzalne osteoporoze (PMO), ukupna incidencija fibrilacije atrija iznosila je 2,5% (96 od 3862) u bolesnica koje su primale zoledronatnu kiselinu u dozi od 5 mg i 1,9% (75 od 3852) u onih koje su primale placebo.
In one 3-year, randomised, double-blind controlled trial that evaluated the efficacy and safety of zoledronic acid 5 mg once yearly vs. placebo in the treatment of postmenopausal osteoporosis (PMO), the overall incidence of atrial fibrillation was 2.5% (96 out of 3,862) and 1.9% (75 out of 3,852) in patients receiving zoledronic acid 5 mg and placebo, respectively.
U randomiziranom, dvostruko slijepom, kontroliranom ispitivanju u trajanju od 3 godine u kojem se ocjenjivala djelotvornost i sigurnost zoledronatne kiseline u dozi od 5 mg jednom godišnje naspram placeba u liječenju osteoporoze u postmenopauzi, ukupna incidencija fibrilacije atrija bila je 2,5% (96 od 3862) u bolesnica koje su primale zoledronatnu kiselinu u dozi od 5 mg, odnosno 1,9% (75 od 3852) u onih koje su primale placebo.
In one 6-month Phase III study, ANORO demonstrated statistically significant improvements in trough FEV1 (primary endpoint) at Week 24 compared with placebo and each monotherapy component treatment arm.
U jednom 6-mjesečnom ispitivanju faze III ANORO je nakon 24 tjedna doveo do statistički značajnih poboljšanja najniže vrijednosti FEV1 (primarna mjera ishoda) u usporedbi s placebom i svakom skupinom koja je primala jednu od sastavnica kao monoterapiju.
In one 6-month Phase III study, LAVENTAIR demonstrated statistically significant improvements in trough FEV1 (primary endpoint) at Week 24 compared with placebo and each monotherapy component treatment arm.
U jednom 6-mjesečnom ispitivanju faze III LAVENTAIR je nakon 24 tjedna doveo do statistički značajnih poboljšanja najniže vrijednosti FEV1 (primarna mjera ishoda) u usporedbi s placebom i svakom skupinom koja je primala jednu od sastavnica kao monoterapiju.
In one case, this resulted in subclinical hepatitis which resolved after a dose interruption.
U jednom slučaju, to je rezultiralo subkliničkim hepatitisom koji se povukao nakon prekida primjene lijeka.
In one clinical study (study 1), 802 patients were treated with Constella 290 micrograms or placebo once daily for 26 weeks.
U jednom kliničkom ispitivanju (ispitivanje 1), 802 bolesnika su liječena lijekom Constella 290 mikrograma ili placebom jedanput na dan tijekom 26 tjedana.
In one clinical study of women with hypogonadotrophic hypogonadism and an endogenous serum LH concentration below 1.2 IU/l the appropriate dose of r-hLH (lutropin alfa) was investigated.
U jednom kliničkom ispitivanju žena s hipogonadotropnim hipogonadizmom i koncentracijom endogenog LH u serumu nižom od 1,2 IU/l, istraživana je odgovarajuća doza r-hLH-a (lutropina alfa).
In one clinical study there was a small (0.38 mmol/l) increase in blood glucose levels at night (3a.m.).
U jednom je kliničkom ispitivanju zabilježen malen porast (0,38 mMol/l) razine glukoze u krvi tijekom noći (u 3 sata ujutro).
In one clinical study, growth and sexual development of paediatric patients treated with deferasirox for up to 5 years were not affected.
U kliničkom ispitivanju rast i spolni razvoj pedijatrijskih bolesnika nije bio oštećen do 5 godina trajanja liječenja deferasiroksom.
In one clinical trial in patients with bipolar mania, valproate combination therapy with olanzapine resulted in an incidence of neutropenia of 4.1%; a potential contributing factor could be high plasma valproate levels.
U jednom kliničkom ispitivanju u bolesnika s bipolarnom manijom, kombinacijska terapija valproata i olanzapina uzrokovala je incidenciju neutropenije od 4,1 %; mogući faktor koji je tome pridonio mogle su biti visoke razine valproata u plazmi.
In one comparative trial, combination therapy with nucleoside analogues (triple therapy with zidovudine plus didanosine) conferred protection against the selection of virus expressing at least one resistance– associated amino acid substitution to both indinavir (from 13/24 to 2/20 at therapy week 24) and to the nucleoside analogues (from 10/16 to 0/20 at therapy week 24).
U jednom je usporednom ispitivanju kombinirano liječenje s nukleozidnim analozima (trojna terapija sa zidovudinom i didanozinom) pružilo zaštitu pred određenim virusima koji eksprimiraju barem jednu aminokiselinsku supstituciju povezanu s rezistencijom na indinavir (od 13/24 do 2/20 u 24. tjednu liječenja) i nukleozidne analoge (od 10/16 do 0/20 u 24. tjednu liječenja).